Milk derived colloid as a novel drug delivery carrier for breast cancer

Masamichi Hayashi, Nissim Silanikove, Xiaofei Chang, Rajani Ravi, Vui Pham, Gilson Baia, Keren Paz, Mariana Brait, David Sidransky, Wayne M. Koch

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Triple negative breast cancer has an extremely poor prognosis when chemotherapy is no longer effective. To overcome drug resistance, novel drug delivery systems based on nanoparticles have had remarkable success. We produced a novel nanoparticle component ‘MDC’ from milk-derived colloid. In order to evaluate the anti-cancer effect of MDC, we conducted in vitro and in vivo experiments on cancer cell lines and a primary tumor derived breast xenograft. Doxorubicin (Dox) conjugated to MDC (MDC-Dox) showed higher cancer cell growth inhibition than MDC alone especially in cell lines with high EGFR expression. In a mouse melanoma model, MDC-Dox significantly suppressed tumor growth when compared with free Dox. Moreover, in a primary tumor derived breast xenograft, one of the mice treated with MDC-Dox showed partial regression, while mice treated with free Dox failed to show any suppression of tumor growth. We have shown that a novel nanoparticle compound made of simple milk-derived colloid has the capability for drug conjugation, and serves as a tumor-specific carrier of anti-cancer drugs. Further research on its safety and ability to carry various anti-cancer drugs into multiple drug-resistant primary breast models is warranted.

Original languageEnglish (US)
Pages (from-to)1184-1193
Number of pages10
JournalCancer Biology and Therapy
Issue number8
StatePublished - 2015


  • Breast cancer
  • Doxil
  • Doxorubicin
  • Milk
  • Nanoparticle
  • Xenograft

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research


Dive into the research topics of 'Milk derived colloid as a novel drug delivery carrier for breast cancer'. Together they form a unique fingerprint.

Cite this